Stay connected and up-to-date on the latest news and reports. It’s never been easier to know what’s going on in digital health.
2024 has been off to a great start at HealthXL, with topics ranging from Tech Enabled Change in Oncology Workflows to a Masterclass: The Legacy of Pear Therapeutics
Read more
ViVE has always been an essential event for digital health decision-makers, offering invaluable insights into the evolving landscape of healthcare.
Read more
2024 has been off to a great start at HealthXL, with topics ranging from How to Scale Partnerships Between Lifesciences and Digital Health Companies? to Real World Data in Clinical Trials: Benefits and Best Practices.
Read more
AI holds the promise of revolutionising clinical trials, specifically by automating and optimising critical processes. The technology has the capability to significantly boost productivity, cut costs, and accelerate the overall timeline of clinical trials.
Read more.png)
Many of you may still be relishing in the holiday bliss, but for HealthXL, the new year is already in full swing. Before we properly close the door on last year, I wanted to take a minute (or so …) to reflect on the tumultuous year that has been.
Read more
As the year draws to a close so does our AI spotlight series. The series catered to many different interests with topics and conversations focused on themes such as Does AI Guarantee ROI and Revolutionising Pharma: AI's Impact on the Value Chain.
Read more
The HealthXL community convened in Princeton, New Jersey. In collaboration with Otsuka, HealthXL organised its fourth Global Gathering of the year around the theme of Leveraging Data-Driven Strategies for Improving Patient Experience.
Read more
By embracing digital measures, pharma can accelerate drug development and improve patient outcomes. Pharma can and will continue to compete on assets, but should not compete on (digital) endpoints. We require industry collaborations in order to usher in a new era of medicine.
Read more
It's been another month of great events at HealthXL, with topics ranging from Enhancing Patient Experiences with Data-Driven Insights to PDT 2.0: The Future of Prescription Digital Therapeutics. To make sure you don't miss the top insights from our community meetings, here are my top five takeaways.
Read more
In a recent masterclass, the discussion revolved around approaches, scalability, and accessibility of digital health solutions in GLP-1 medication and obesity management. In this article, we highlight the key insights shared during the session.
Read more
While the healthtech sector has evolved significantly in the past few years, 2023 looks set to be another year of significant change. At our Global Gathering in Munich, startups, pharma, and investors split up into several roundtables, tackling the several topics. Here is what we learned.
Read more.png)
Pear Therapeutics announced last week that they are looking into “strategic alternatives” that could bolster its current precarious financial situation. Pear has been on the public markets since late 2021, however, its stock price has declined over the last two years.
Read more.png)
FDIC's decision to close SVB has had an immediate impact on startup and tech companies, including those in digital health. With rising interest rates, investors have become increasingly conservative with their investments, focusing on a more targeted investment strategy.
Read more
Mental health has been a pioneering area for digital therapeutics and a keen area of focus for digital health in recent years. As per the latest industry reports, the global market for digital biomarkers is growing, with its value estimated to reach $16,174 million by 2028.
Read more.png)
There was a wide range of topics discussed at our HealthXL meetings this February. To make sure you’re not missing out on the insightful discussions between community members and to keep you plugged into the conversation, here are Tess' five meeting takeaways from the past month.
Read more
A key component to ensuring the adoption of digital health products is market access and reimbursement. In this week’s blog, we explore France's new fast-track reimbursement pathway for digital health and how it compares to Germany's DiGA pathway.
Read more.png)
The HealthXL Sprint 2-part meeting series connects senior leaders across our community to solve the latest health challenges. In our most recent sprint, we discussed the pharma sales models for DTx-drug combination products. In this blog, we’ve pulled out the top takeaways from this series.
Read more
Over the past month, our HealthXL community members have discussed the opportunities for digital health in retail healthcare, using real-world data (RWD) to increase market access and revenue generation in DTx partnerships among other topics. Here's a snapshot of expert insights from these meetings.
Read more